p

Prostate cancer and prostatic diseases

Prostate cancer and prostatic diseases

Benign prostate hyperplasia (bph) and prostate cancer for

Prostate Cancer and Prostatic Diseases is a peer-reviewed medical journal that covers prostate cancer and other prostate-related disorders on a quarterly basis. It started in 1997, with Roger Kirby as the founding editor[1], and in 2003, Judd Moul joined Kirby as a co-editor. [two] Nature Publishing Company is the publisher. Stephen Freedland is the editor-in-chief (Cedars-Sinai Medical Center). The journal has a 2015 impact factor of 3.803, which places it 15th out of 76 journals in the category “Urology & Nephrology” according to Journal Citation Reports. [three]

Prostate problems

Prostate Cancer and Prostatic Diseases encompasses all aspects of prostatic diseases, especially prostate cancer, which is the focus of extensive basic and clinical research around the world. The journal also covers cutting-edge research in diagnosis, surgery, radiotherapy, drug growth, and medical management.
Prostate Cancer and Prostatic Diseases is a book for surgeons, oncologists, and physicians who treat prostate cancer patients, as well as those who work in prostate cancer science. Prostate cancer, male LUTS, and prostatitis are the three primary subjects discussed in the journal.
The collection of journals was ranked and divided into four equal classes, or quartiles, based on their SJR. The highest values are in Q1 (green), followed by the second highest values in Q2 (yellow), the third highest values in Q3 (orange), and the lowest values in Q4 (red).
The SJR is a prestige metric that rates journals based on their ‘average prestige per paper’ regardless of their size. It is founded on the theory that “not all citations are created equal.” SJR is a measure of a journal’s scientific impact that takes into account both the amount of citations it earns and the importance or reputation of the journals from which those citations come.

Signs and symptoms of prostate cancer | dana-farber

Prostate Cancer and Prostatic Diseases encompasses all aspects of prostatic diseases, especially prostate cancer, which is the focus of extensive basic and clinical research around the world. The journal also covers cutting-edge research in diagnosis, surgery, radiotherapy, drug growth, and medical management.
Prostate Cancer and Prostatic Diseases is a book for surgeons, oncologists, and physicians who treat prostate cancer patients, as well as those who work in prostate cancer science. Prostate cancer, BPH, and prostatitis are the three primary subjects discussed in the journal.
Original research papers, reviews, topical commentary, and critical appraisals of scientific meetings and the most recent books are published in Prostate Cancer and Prostatic Diseases. A calendar of upcoming scientific meetings is also included in the journal. The Editors and a distinguished Editorial Board ensure that submitted papers are dealt with easily and effectively, and that they are refereed to the highest scientific standard possible. For timely articles of particular importance, a fast track system is accessible.

Prostate health: mayo clinic radio

Note: The impact factor shown here is similar to citescore and is hence used as a substitute for it. Scopus calculates Citescore, which can be slightly higher or lower than the impact factor calculated by Journal Citation Report. Please verify the exact journal impact factor TM (Thomson Reuters) metric using the Web of Science data base.
Prostate Cancer and Prostatic Diseases is a journal that covers cancer research (Q1), oncology (Q1), and urology (Q1) technologies, areas, and categories (Q1). Nature Publishing Company is the publisher. Prostate Cancer and Prostatic Diseases were ranked 1159th overall.
This journal is ranked 2.2 on the SCImago Journal Rank (SJR) system. The SCImago Journal Rank is a metric that assesses a journal’s scientific impact. It takes into account the amount of citations a journal receives as well as the relevance of the journals from which these citations originate. SJR is a replacement for the Journal Impact Factor (or an average number of citations received in last 2 years). The h-index of this journal is 56. Q1 is the best quartile for this journal.